Last reviewed · How we verify

NCT06022575

Telehealth Integrated Care Model in Patients With Cardiometabolic Disease

Status unknown Last updated 5 September 2023
What this trial tests

trial testing Telehealth integrated care in Cardiometabolic Disease in 1,302 participants. Status unknown.

Timeline
20 June 2023
Primary endpoint
20 June 2024
20 July 2025

Quick facts

Lead sponsorPeking University Third Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,302
Start date20 June 2023
Primary completion20 June 2024
Estimated completion20 July 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 16 to 85, any sex, with Cardiometabolic Disease or Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. The result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiometabolic Disease

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06022575.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing